drugset / Trial / NCT06212596

Selinexor, Cyclophosphamide and Prednisone in Myeloma

NCT06212596

Phase 2 Completed 66 enrolled University of Leeds
RandomizedParallel-groupOpen-labelTreatment

Summary

The trial is designed as a randomised, controlled, open, parallel group, multi-centre phase II trial to evaluate clinical efficacy of selinexor in combination with cyclophosphamide and prednisone.

Timeline

Start
2018-07-16
Primary completion
2022-10-25
Completion
2023-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified Oral
Background Cyclophosphamide Other / unclassified
Background Prednisone Other / unclassified